Not applicableStudy completedNCT02215226What this trial is testingGBS Sero-correlate of ProtectionWho this might be right forInvasive Group B Streptococcus Disease University of Witwatersrand, South Africa 35,274
Not applicableLooking for participantsNCT06833957What this trial is testingPreparing for Maternal GBS Vaccine Trials in AfricaWho this might be right forGroup B StreptococcusInvasive Bacterial Diseases (IBD)Maternal Immunization Barcelona Institute for Global Health 18,100
Not applicableStudy completedNCT01888471What this trial is testingFeasibility Study for Identifying Anti Capsular Antibody Protection Against Invasive Group B Streptococcus (GBS) Disease in Newborns of 0-6 Days Age (Early Onset Disease [EOD]) as Well as Among Infants of 7-90 Days Age (Late Onset Disease [LOD])Who this might be right forStreptococcus Agalactiae GlaxoSmithKline 3,033
Not applicableUnknownNCT04653948What this trial is testingMaternal, Neonatal and Infant Outcomes at Kawempe National Referral HospitalWho this might be right forGroup B Streptococcus Carrier in ChildbirthGroup B Streptococcal Infection, Late-OnsetGroup B Streptococcal Infection, Early-Onset+2 more St George's, University of London 3,423
Not applicableStudy completedNCT01933646What this trial is testingBurden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in ChinaWho this might be right forInvasive Group B Streptococcal Disease Novartis Vaccines 10
Early research (Phase 1)Study completedNCT00645346What this trial is testingA Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of AgeWho this might be right forInvasive Group B Streptococcus (GBS) Disease Novartis Vaccines 130
Early research (Phase 1)Study completedNCT00657683What this trial is testingA Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of AgeWho this might be right forInvasive Group B Streptococcus (GBS) Disease Novartis Vaccines 65
Not applicableNot Yet RecruitingNCT06896526What this trial is testingComprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) RegistryWho this might be right forInvasive Group B Streptococcus DiseaseGroup B StreptococcusGroup B Streptococcal Infection+3 more Precia Group 10,000